Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Acquisitions & Divestments: 2010-2025

Historic Change in Acquisitions & Divestments for Gyre Therapeutics (GYRE) over the last 7 years, with Mar 2025 value amounting to $11.2 million.

  • Gyre Therapeutics' Change in Acquisitions & Divestments was N/A to $11.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $24.1 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2022, which is 94.89% down from last year.
  • Per Gyre Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $11.2 million for Q1 2025, which was up 346.88% from $2.5 million recorded in Q1 2022.
  • Gyre Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $27.6 million for Q1 2021, and its period low was $2.5 million during Q1 2022.
  • Moreover, its 1-year median value for Change in Acquisitions & Divestments was $11.2 million (2025), whereas its average is $11.2 million.
  • Data for Gyre Therapeutics' Change in Acquisitions & Divestments shows a maximum YoY slumped of 91.44% (in 2021) over the last 5 years.
  • Gyre Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $2.9 million in 2021, then tumbled by 90.92% to $2.5 million in 2022, then reached $11.2 million in 2025.
  • Its Change in Acquisitions & Divestments was $11.2 million in Q1 2025, compared to $2.5 million in Q1 2022 and $2.9 million in Q4 2021.